Skip to main content
. 2019 Jan 1;9(1):290–310. doi: 10.7150/thno.28671

Table 1.

Subcutaneously delivered iPSCs formed teratomas. s.c.: subcutaneous.

iPSC type Recipient animal Route of administration Dose Frequency of administration Matrigel Disease model Time of observation Number of animals Rate of teratoma
formation
C57BL/6-1 Male, C57BL/6 s.c. 1×106/spot Single Yes, 100 μL None 28 days 10 100%
C57BL/6-1 Male, C57BL/6 s.c. 1×106/spot Single No, but in 100 μL PBS None 28 days 10 100%
C57BL/6-1 Female, C57BL/6 s.c. 1×106/spot Single Yes, 100 μL None 28 days 10 100%
C57BL/6-1 Male, SCID-NOD s.c. 1×106/spot Single Yes, 100 μL None 28 days 10 100%
C57BL/6-1 derivatives Male, C57BL/6 s.c. 1×106/spot Single Yes, 100 μL None 180 days 10 0%
C57BL/6-2 Male, C57BL/6 s.c. 1×106/spot Single Yes, 100 μL None 28 days 10 100%
C57BL/6-2 Female, C57BL/6 s.c. 1×106/spot Single Yes, 100 μL None 28 days 10 100%
C57BL/6-2 Male, SCID-NOD s.c. 1×106/spot Single Yes, 100 μL None 28 days 10 100%
Healthy human iPSC-1 Male, SCID-NOD s.c. 1×106/spot Single Yes, 100 μL None 28 days 10 80%
Healthy human iPSC-2 Male, SCID-NOD s.c. 1×106/spot Single Yes, 100 μL None 28 days 10 90%
iPSCs from 4 different type 2 diabetic patients Male, SCID-NOD s.c. 5×106/spot Single Yes, 100 μL None 28 days 4 100%
Autologous iPSCs from 4 different monkeys Individualized, monkey from which cells were used for iPSC induction s.c. 1×105/spot Single No, but in
100 μL PBS		 None 180 days 4 0%
Autologous iPSCs from 4 different monkeys Individualized, monkey from which cells were used for iPSC induction s.c. 5×106/spot Single Yes, 100 μL None 28 days 4 100%
C57BL/6-1 Male, C57BL/6 s.c. 1×105/spot Single No, but in
100 μL PBS		 None 28 days 10 0%
C57BL/6-1 Male, C57BL/6 s.c. 1×105/spot Single Yes, 100 μL None 28 days 3 30%